Insys Therapeutics, Inc.
|$421 M||Market Cap|
|N/A||EBIT / EV|
|4.1%||FCF / EV|
|48.6%||3yr Avg Revenue Growth|
Business Model Diligence
We do not yet have Business Model Diligence for this stock.
|Cannot calculate EBIT / Enterprise Value, company has negative EBIT.|
|The Free Cash Flow / Enterprise Value of 4.1% ranks as Average.|
|Cannot calculate Return on Invested Capital, company has negative EBIT.|
|The Cash Return on Capital Value of 19.7% ranks as Above Average.|
|The 3 Year Average Revenue Growth Value of 48.6% ranks as Very High.|
|Near-term Financial Health appears to be Worrisome. The Current Ratio is 0.86.|
INSYS Therapeutics, Inc. is a c pharmaceutical company, which develops and commercializes supportive care products. It focuses on utilizing commercial pharmaceutical products. The company markets Subsys, a proprietary sublingual fentanyl spray for breakthrough pain in opioid-tolerant cancer patients; and Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol. It offers its Subsys through its incentive-based commercial sales force. The company also provides Dronabinol SG Capsule, a generic equivalent to Marinol, an approved second-line treatment for chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. INSYS Therapeutics was founded by John N. Kapoor on June 15, 1990 and is headquartered in Chandler, AZ.
|Cognex Corporation (CGNX)|
|iRobot Corporation (IRBT)|
|Target Corporation (TGT)|
|Buckle, Inc. (BKE)|
|Talend SA Sponsored ADR (TLND)|